{
  "question": "问题",
  "yes": "是",
  "no": "否",
  "yesAlways": "是，始终",
  "yesInAllCases": "是，在所有情况下",
  "yesToSomeExtent": "是，某种程度上",
  "inSomeCasesOnly": "仅在某些情况下",
  "inSomeCases": "在某些情况下",
  "yesInSomeCases": "是，在某些情况下",
  "provideWebsiteAddress": "请提供网址",
  "bilateral": "双边渠道",
  "regional": "区域渠道",
  "multilateral": "多边渠道",
  "oneToFour": "1 至4",
  "oneToFive": "1 至 5",
  "fiveToNine": "5 至9",
  "tenOrMore": "10人或以上",
  "fiveOrMore": "5人或以上",
  "oneToNine": "1 至9",
  "tenTenFortyNine": "10 至49",
  "fiftyToNinetyNine": "50 至 99",
  "fiftyOrMore": "50 个或 50 个以上",
  "hundredOrMore": "100人或以上",
  "other": "其他",
  "none": "无",
  "noneDecisions": "无（不经磋商而作出决定）",
  "riskAssessment": "风险评估：",
  "riskManagement": "风险管理：",
  "monitoring": "监测：",
  "isThisNumberAdequate": "人数够用吗：",
  "documentationSpecificToLMOs": "专门的改性活生物体单据",
  "asPartOfOtherDocumentation": "作为其他单据的一部分（并非专门的改性活生物体单据）",
  "provideFurtherInformation": "请提供更多信息",
  "informationOnInstruments": "请提供已出台文书的更多信息",
  "general": "一般信息",
  "country": "国家",
  "notApplicable": "不适用（没有作过决定）",
  "notApplicableOnly": "不适用",
  "availableOnBch": "有信息且已向生物安全信息交换所提交",
  "availablePartialyOnBch": "有信息但只部分提交生物安全信息交换所",
  "availableNotOnBch": "有信息但尚未提交生物安全信息交换所",
  "notAvailable": "没有信息",
  "institutionalCapacity": "机构能力和人力资源",
  "integrationOfBiosafetyInCrossSectoral": "将生物安全纳入跨部门和部门立法、政策及机构（将生物安全纳入主流）",
  "riskAssessmentExpertise": "风险评估及其他科学技术专业知识",
  "publicAwarenessBiosafety": "生物安全方面的公众认识、参与和教育",
  "informationExchangeAndDataManagement": "信息交流和数据管理，包括参与生物安全信息交换所的活动",
  "regionalAdInternationalLevels": "在次区域、区域和国际层次上的科学、技术和机构合作",
  "technologyTransfer": "技术转让",
  "identificationOfLMOsDetection": "改性活生物体的识别，包括其检测",
  "socioeconomicConsiderations": "社会-经济因素",
  "implementationProtocol": "执行《议定书》第18.2条的单据要求",
  "handlingConfidentialInformation": "机密资料的处理",
  "measuresOfLMOs": "改性活生物体无意和/或非法越境转移的应对措施",
  "scientificLMOs": "与改性活生物体相关的科学生物安全研究",
  "takingHHumanealth": "考虑对人类健康的风险",
  "liabilityAnRedress": "赔偿责任和补救",
  "article2_title": "第2条 — 一般规定",
  "article2_description": "<i>第2条要求每一缔约方为履行本议定书为之规定的各项义务采取必要和适当的法律、行政和其他措施。</i>",
  "article2_question7_title": "贵国是否已采取必要的国家措施执行议定书？",
  "article2_question7_options0_title": "国家措施充分到位",
  "article2_question7_options1_title": "国家措施部分到位",
  "article2_question7_options2_title": "仅采取了临时措施",
  "article2_question7_options3_title": "仅有措施草案",
  "article2_question7_options4_title": "未采取任何措施",
  "article2_question8_title": "贵国已制定哪些用于执行国家生物安全措施的具体文书（选择所有适用选项）？",
  "article2_question8_options0_title": "一部或多部国家生物安全法律",
  "article2_question8_options1_title": "一部或多部国家生物安全条例",
  "article2_question8_options2_title": "一套或多套生物安全准则",
  "article2_question8_options3_title": "间接适用于生物安全的其他法律、条例或准则",
  "article2_question8_options4_title": "未制定任何文书",
  "article2_question9_title": "贵国是否已将生物安全纳入国家部门和跨部门战略、行动计划、方案、政策或立法？",
  "article2_question10_title": "贵国国家预算是否为生物安全编列资金？",
  "article2_question10_question0_title": "资金是否充足：",
  "article2_question11_title": "贵国是否设有合格工作人员管理与生物安全直接相关的职能？",
  "article2_question12_title": "若您对第11个问题的回答为<i>是</i>，那么其职能与生物安全直接相关的合格工作人员有多少",
  "article2_question13_title": "请在此提供贵国执行第2条的更多细节：",
  "article5_title": "第5条 — 药物",
  "article5_question14_title": "贵国是否规范了作为人类药物的改性活生物体的越境转移、处理或使用？",
  "article5_question15_title": "请在此提供贵国执行第5条的更多细节：",
  "article6_title": "第6条 — 过境和封闭使用",
  "article6_question16_title": "贵国是否规范了改性活生物体的过境？",
  "article6_question17_title": "贵国是否规范了改性活生物体的封闭使用？",
  "article6_question18_title": "贵国是否已经就进口用于封闭使用的改性活生物体作出决定？",
  "article6_question19_title": "请在此提供贵国执行第6条的更多细节：",
  "articles7_10_title": "第7至10条：事先知情同意及有意向环境中引入改性活生物体",
  "articles7_10_question20_title": "贵国是否已为其所管辖的出口者规定了法律要求，在有意越境转移属于事先知情同意程序范围内的改性活生物体之前以书面形式通知进口缔约方的国家主管部门？",
  "articles7_10_question21_title": "作为出口缔约方时，贵国是否已就出口者提供的通知中所载信息的准确性规定了法律要求？",
  "articles7_10_question22_title": "本报告所述期间，贵国是否收到过有意向环境中引入改性活生物体的有意越境转移的相关通知？",
  "articles7_10_question23_title": "若您对第22个问题的回答为“<i>是</i>”，那么通知是否载有完整信息（至少载有《卡塔赫纳生物安全议定书》附件一具体规定的信息）？",
  "articles7_10_question24_title": "若您对第22个问题的回答为“<i>是</i>”，那么贵国是否会在收到通知九十天之内向通知人确认收到该通知？",
  "articles7_10_question25_title": "若您对第22个问题的回答为“<i>是</i>”，那么贵国是否向以下方面通报了本国的决定：",
  "articles7_10_question25_question0_title": "通知人？",
  "articles7_10_question25_question1_title": "生物安全信息交换所？",
  "articles7_10_question26_title": "本报告所述期间，贵国是否针对关于有意向环境中引入改性活生物体的有意越境转移的通知作出决定？",
  "articles7_10_question26_question0_title": "请说明数量",
  "articles7_10_question27_title": "如果您对第26个问题的回答为“<i>是</i>”，那么贵国以下类别决定所占的百分比是多少？",
  "articles7_10_question27_question0_title": "无条件准予进口/使用改性活生物体",
  "articles7_10_question27_question1_title": "有条件准予进口/使用改性活生物体",
  "articles7_10_question27_question1_question0_title": "是否说明这些条件的理由?",
  "articles7_10_question27_question2_title": "禁止进口/使用改性活生物体",
  "articles7_10_question27_question2_question0_title": "是否说明禁止的理由?",
  "articles7_10_question27_question3_title": "要求提供更多相关资料",
  "articles7_10_question27_question4_title": "告知通知人延期通报决定",
  "articles7_10_question28_title": "若您对第26个问题的回答为“<i>是</i>”，那么贵国已核准进口多少种有意向环境中引入的改性活生物体？",
  "articles7_10_question29_title": "若您在对第28个问题的回答为核准了改性活生物体，那么经核准的改性活生物体是否实际进口至贵国？",
  "articles7_10_question30_title": "请在此提供贵国执行第7条至第10条的更多细节，包括在对有意向环境中引入的改性活生物体的潜在不利影响没有科学上的把握时采取的措施：",
  "article11_title": "第11条 — 关于拟直接作食物或饲料或加工之用的改性活生物体的程序",
  "article11_question31_title": "贵国是否订有法律、条例或行政措施，用于对予以越境转移的拟直接作食物或饲料或加工之用的改性活生物体的国内用途（包括投放市场）作出决定？",
  "article11_question32_title": "贵国是否就申请者所提供关于可能予以越境转移的拟直接作食物或饲料或加工之用的改性活生物体的国内用途（包括投放市场）之资料的准确性规定了法律要求？",
  "article11_question33_title": "本报告所述期间，贵国已就可能予以越境转移的拟直接作食物或饲料或加工之用的改性活生物体的国内用途（包括市场投放）作出过多少项决定？",
  "article11_question34_title": "贵国是否订有法律、条例或行政措施，用于对拟直接作食物或饲料或加工之用的改性活生物体的进口作出决定？",
  "article11_question35_title": "本报告所述期间，贵国已就拟直接作食物或饲料或加工之用的改性活生物体的进口作出过多少项决定？",
  "article11_question36_title": "请在此提供贵国执行第11条的更多细节，包括在对可能予以越境转移的拟直接作食物或饲料或加工之用的改性活生物体的潜在不利影响没有科学上的把握时采取的措施：",
  "article12_title": "第12条 — 对决定的复审",
  "article12_question37_title": "贵国是否已建立相关机制用于审查并更改其已就改性活生物体的有意越境转移所作出的决定？",
  "article12_question38_title": "本报告所述期间，贵国是否审查和/或更改过就改性活生物体的有意越境转移所作出的决定？",
  "article12_question39_title": "若您对第38个问题的回答为“<i>是</i>”，那么对多少项决定进行过审查和/或更改？",
  "article12_question40_title": "若您对第38个问题的回答为“<i>是</i>”，那么是否有因出口缔约方或通知人的要求而引发的审查？",
  "article12_question41_title": "若您对第40个问题的回答为“<i>是</i>”，那么贵国是否在九十天之内作出回复并说明决定的理由？",
  "article12_question42_title": "若您对第38个问题的回答为“<i>是</i>”，那么是否存在由贵国作为进口缔约方启动的审查？",
  "article12_question43_title": "若您对第42个问题的回答为“<i>是</i>”，那么贵国是否在三十天之内说明决定的理由并通报:",
  "article12_question43_question0_title": "通知人？ ",
  "article12_question43_question1_title": "生物安全信息交换所？",
  "article12_question44_title": "请在此提供贵国执行第12条的更多细节：",
  "article13_title": "第13条 — 简化程序",
  "article13_question45_title": "贵国是否已就改性活生物体的有意越境转移简化程序建立了应用系统？",
  "article13_question46_title": "本报告所述期间，贵国是否已经应用简化程序？",
  "article13_question47_title": "若您对第46个问题的回答为“<i>是</i>”，那么贵国对多少种改性活生物体适用了简化程序？",
  "article13_question48_title": "若您对第46个问题的回答为“<i>是</i>”，那么贵国是否曾通过生物安全信息交换所向缔约方通报了适用该简化程序的相关案例？",
  "article13_question49_title": "人数是否够用：请在此提供贵国执行第13条的更多细节：",
  "article14_title": "第14条 — 双边、区域及多边协定和安排",
  "article14_question50_title": "贵国与其他缔约方/非缔约方订立了多少项与生物安全相关的双边、区域或多边协定或安排？",
  "article14_question51_title": "若您对 第50个问题 的回答为 <i>订立了协定或安排</i>，请简要描述所订立协定或安排的范围和目标:",
  "article14_question52_title": "人数是否够用：请在此提供贵国执行第14条的更多细节：",
  "articles15_16_title": "第15和16条 — 风险评估和风险管理",
  "articles15_16_question53_title": "贵国的国内监管框架是否要求对改性活生物体开展风险评估？",
  "articles15_16_question53_a_title": "该要求适用于哪些改性活生物体（请选择所有适用的改性活生物体）",
  "articles15_16_question53_a_option0_title": "进口有意向环境中引入的改性活生物体",
  "articles15_16_question53_a_option1_title": "进口拟直接作食物或饲料或加工之用的改性活生物体",
  "articles15_16_question53_a_option2_title": "关于可能予以越境转移的拟直接作食物或饲料或加工之用的改性活生物体的国内用途（包括市场投放）之决定",
  "articles15_16_question53_a_option3_title": "进口用于封闭使用的改性活生物体",
  "articles15_16_question54_title": "贵国是否已经建立机制用于在作出与改性活生物体相关的决定之前开展风险评估？",
  "articles15_16_question55_title": "本报告所述期间，贵国是否曾对改性活生物体开展过任何风险评估，包括针对改性活生物体开展的用于封闭使用、现场试验、商业目的、拟直接作食物或饲料或加工之用等类型的风险评估？",
  "articles15_16_legend_55_68": "<i>开展风险评估或风险管理</i>",
  "articles15_16_question56_title": "若您对第55个问题的回答为“<i>是</i>”，那么贵国已开展过多少次风险评估？",
  "articles15_16_question57_title": "若您对第55个问题的回答为“<i>是</i>”，那么请指出这些风险评估的范围（请选择所有适用项）:",
  "articles15_16_question57_option0_title": "用于封闭使用的改性活生物体（根据第3条）",
  "articles15_16_question57_option1_title": "有意向环境中引入以进行实验测试或现场试验的改性活生物体",
  "articles15_16_question57_option2_title": "出于商业目的有意向环境中引入的改性活生物体",
  "articles15_16_question57_option3_title": "拟直接用作食物的改性活生物体",
  "articles15_16_question57_option4_title": "拟直接用作饲料的改性活生物体",
  "articles15_16_question57_option5_title": "拟作加工之用的改性活生物体",
  "articles15_16_question58_title": "若您对第55个问题的回答为“<i>是</i>”，那么是否针对关于有意向环境中引入的改性活生物体或者可能予以越境转移的拟直接作食物或饲料或加工之用的改性活生物体的国内用途（包括投放市场）的所有决定开展了风险评估？",
  "articles15_16_question59_title": "若您对第55个问题的回答为“<i>是</i>”，那么您是否考虑过：",
  "articles15_16_question59_a_title": "议定书第15条中提到的其他现有科学证据？",
  "articles15_16_question59_b_title": "土著人民和地方社区的相关传统知识？ ",
  "articles15_16_question60_title": "如果您对问题59（b）回答为<i>是</i>或<i>在某些情况下是</i>，那么是否以科学合理和透明的方式考虑了这一信息？",
  "articles15_16_question61_title": "贵国是否已经建立了适当的机制、措施和战略以规范和管理在改性活生物体风险评估中识别的风险？",
  "articles15_16_question62_title": "贵国是否已采取了适当的措施以防止改性活生物体无意中造成的越境转移，包括要求在首次释放改性活生物体之前开展风险评估等措施？<sup>1</sup>",
  "articles15_16_question62_footnote_1": "<sup>1</sup> 无意中造成的越境转移的工作定义见脚注5。",
  "articles15_16_question63_title": "贵国是否采取了措施来确保任何改性活生物体（无论是进口的还是本地研制的）在用作预期用途之前均接受与其生命周期或增代时间相应的适当期限的观察？",
  "articles15_16_question64_title": "贵国是否建立了机制来监测释放至环境中的改性活生物体的潜在影响？",
  "articles15_16_question65_title": "贵国是否具有识别可能对生物多样性的保护和可持续利用造成不利影响的改性活生物体或具体特性的措施？",
  "articles15_16_question66_title": "贵国是否为开展风险评估或风险管理或为评估通知人提交的风险评估报告而查阅或使用参考资料，包括指导文件？",
  "articles15_16_question67_title": "若您对第66个问题（a）或（b）的回答为<i>是</i>，那么贵国进行风险评估或风险管理或评价通知人提交的风险评估时是否使用了“改性活生物体风险评估指南”（由风险评估和风险管理特设技术专家组网络论坛编制）<sup>2</sup>？",
  "articles15_16_question67_footnote_2": "<sup><sup>2</sup><a target='_blank' href=’https://www.cbd.int/doc/meetings/bs/mop-08/official/bs-mop-08-08-add1-zh.pdf'> UNEP/CBD/COP-MOP/8/8/Add.1.</a>号文件</a>",
  "articles15_16_question68_title": "贵国在改性活生物体风险评估的具体专题方面是否需要进一步的具体指导？",
  "articles15_16_legend_69_72": "<i>风险评估或风险管理方面的能力建设</i>",
  "articles15_16_question69_title": "考虑到对人类健康造成的风险，贵国是否具有检测、识别、评估和/或监测可能对生物多样性的保护和可持续利用造成不利影响的改性活生物体或具体特性的能力？",
  "articles15_16_question69_a_title": "检测：",
  "articles15_16_question69_b_title": "识别：",
  "articles15_16_question69_c_title": "评估风险：",
  "articles15_16_question69_d_title": "监测：",
  "articles15_16_question70_title": "本报告所述期间，贵国有多少人接受了改性活生物体风险评估、风险管理和监测培训？",
  "articles15_16_question71_title": "贵国是否在改性活生物体风险评估和风险管理培训中使用了培训材料和/或技术指南？",
  "articles15_16_question71_question0_title": "用了哪些材料/指南：",
  "articles15_16_question71_question0_option0_title": "CBD秘书处编写的改性活生物体风险评估手册<sup>3</sup>",
  "articles15_16_question71_question0_option1_title": "风险评估和风险管理在线论坛和特设技术专家组编写的改性活生物体风险评估指南<sup>4</sup>",
  "articles15_16_question71_footnote_3": "<sup><sup>3</sup><a <a target='_blank' href='https://www.cbd.int/doc/meetings/bs/mop-07/information/mop-07-inf-06-zh.pdf'> UNEP/CBD/BS/COP-MOP/7/INF/6.</a>号文件</a>",
  "articles15_16_question71_footnote_4": "<sup><sup>4</sup><a target='_blank' href=’https://www.cbd.int/doc/meetings/bs/mop-08/official/bs-mop-08-08-add1-zh.pdf'> UNEP/CBD/COP-MOP/8/8/Add.1.</a>号文件</a>",
  "articles15_16_question71_question0_option2_title": "其他材料/指南：",
  "articles15_16_question72_title": "请在此提供贵国执行第15和第16条的更多细节：",
  "article17_title": "第17条 - 无意中造成的越境转移<sup>5</sup>和应急措施",
  "article17__footnote_5": "<sup>5</sup> 根据第CP-VIII/16号决定通过的工作定义，“‘无意中造成的越境转移’指的是无意中跨越了某个缔约方的国界，造成改性活生物体释放的越境转移。只有在所涉改性活生物体可能对生物多样性的保护和可持续利用产生重大有害影响的情况下，才对此种越境转移适用《议定书》第17条的规定，同时顾及受影响或可能受影响国家的人类健康风险”。",
  "article17_question73_title": "贵国是否已经建立措施，在其管辖范围内发生的某一释放将会导致或可能导致无意中造成的越境转移时，向受到影响或可能会受到影响的国家、生物安全信息交换所并酌情向有关的国际组织发出通知？",
  "article17_question74_title": "本报告所述期间，在贵国管辖范围内发生了多少次导致或可能会导致无意越境转移的改性活生物体释放？",
  "article17_question75_title": "若您对 <i>第74个问题</i> 的回答为 <i>发生了释放</i>，那么贵国是否通知了受到影响或可能会受到影响的国家、生物安全信息交换所并酌情通知有关国际组织？",
  "article17_question76_title": "本报告所述期间，贵国多少次意识到无意中造成的越境转移进入其领土？",
  "article17_question77_title": "贵国是否有能力采取适当措施应对无意中造成的越境转移？",
  "article17_question78_title": "请在此提供贵国执行第17条的更多细节：",
  "article18_title": "第18条 — 处理、运输、包装和标志",
  "article18_question79_title": "贵国是否参照有关国际规则和标准，采取措施要求在安全的条件下处理、包装和运输属于拟越境转移的改性活生物体？",
  "article18_question80_title": "贵国是否采取措施要求拟直接作食物或饲料或加工之用的改性活生物体所附单据，在 <i>改性活生物体名称 <u>无法获知的情况下</u></i>明确说明其中 <i>可能含有改性活生物体</i> 且不打算有意将其引入环境，并附上供进一步获取信息的联络点？",
  "article18_question81_title": "贵国是否采取措施要求拟直接作食物或饲料或加工之用的改性活生物体所附单据，在 <i>改性活生物体名称 <u>获知的情况下</u></i>明确说明其中 <i>含有改性活生物体</i> 且不打算有意将其引入环境，并附上供进一步获取信息的联络点？",
  "article18_question82_title": "若您对第79、80和/或81个问题的回答为<i>是</i>或<i>在某种程度上是</i>，那么贵国要求改性活生物体须附有哪些单据？",
  "article18_question83_title": "贵国是否采取措施要求<i>预定用于封闭使用</i>的改性活生物体所附单据明确将其标明为<i>改性活生物体</i>，并具体说明安全处理、储存、运输和使用的任何要求，以及供进一步索取信息的联络人（包括接收改性活生物体的个人和机构名称和地址）？",
  "article18_question84_title": "若您对第83个问题的回答为<i>是</i>或<i>在某种程度上是</i>，那么贵国要求哪些类别的识别预定用于封闭使用的改性活生物体的单据？",
  "article18_question85_title": "贵国是否采取措施要求<i>有意向进口缔约方环境中引入</i>的改性活生物体所附单据明确将其标明为<i>改性活生物体</i>；具体说明其名称和相关特性和/或特点、关于安全处理、储存、运输和使用的任何要求以及供进一步索取信息的联络人，并酌情提供进口者和出口者名称和地址；以及列出关于所涉转移符合《卡塔赫纳议定书》中适用于出口者的规定的声明？",
  "article18_question86_title": "若您对第85个问题的回答为<i>是</i>或<i>在某种程度上是</i>，那么贵国要求哪些类别的识别有意引入环境的改性活生物体的单据？",
  "article18_question87_title": "贵国是否有能力实施改性活生物体识别和单据方面的要求？",
  "article18_question88_title": "本报告所述期间，贵国有多少名海关人员接受识别改性活生物体的培训？",
  "article18_question89_title": "贵国是否建立了改性活生物体的采样和检测程序？",
  "article18_question90_title": "贵国是否能够获得和使用资料和检测方法来检测和识别改性活生物体？",
  "article18_question90_a_title": "<i>获得</i>参考材料和检测方法来检测和识别改性活生物体?",
  "article18_question90_b_title": "<i>使用</i>参考材料和检测方法来检测和识别改性活生物体?",
  "article18_question91_title": "贵国是否能够获得和使用检测和识别改性活生物体的工具?",
  "article18_question91_a_title": "<i>获得</i>工具？",
  "article18_question91_b_title": "<i>使用</i>工具？",
  "article18_question92_title": "贵国是否能够获得并使用检测和识别改性活生物体所需的经认证的参考材料？",
  "article18_question92_a_title": "<i>获得</i>经认证的参考材料？",
  "article18_question92_b_title": "<i>使用</i>经认证的参考材料？",
  "article18_question93_title": "贵国有多少名实验室人员接受过检测改性活生物体的培训？",
  "article18_question94_title": "贵国是否拥有可靠途径使用检测和识别改性活生物体的技术设施，例如实验室？",
  "article18_question94_a_title": "<i>检测</i>改性活生物体的技术设施？",
  "article18_question94_b_title": "<i>识别</i>改性活生物体的技术设施?",
  "article18_question95_title": "贵国有多少个经认证的检测改性活生物体的实验室？",
  "article18_question96_title": "若您对第95个问题的回答为<i>贵国拥有经认证的实验室</i>，那么其中有多少个目前在进行改性活生物体检测？",
  "article18_question97_title": "请在此提供贵国执行第18条的更多细节：",
  "article19_title": "第19条 — 国家主管部门和国家联络人",
  "article19_question98_title": "如贵国已指定一个以上的国家主管部门，那么贵国是否已经建立相关机制以在就改性活生物体作出决定之前对所述主管部门的行动进行协调？",
  "article19_question98_option0_title": "不适用，未指定国家主管部门",
  "article19_question98_option1_title": "不适用，只指定一个国家主管部门",
  "article19_question99_title": "贵国是否已建立充分的机构能力，使国家主管部门能够执行《卡塔赫纳生物安全议定书》所要求的行政职能？",
  "article19_question100_title": "贵国是否已采取举措加强国家联络人、国家主管部门以及其他生物安全事务相关机构之间的协作？",
  "article19_question101_title": "请在此提供贵国执行第19条的更多细节：",
  "article20_title": "第20条 — 信息共享与生物安全信息交换所",
  "article20_question102_title": "请概述贵国向生物安全信息交换所提供规定信息的情况，具体说明是否有各类信息<sup>6</sup>，是否已提交生物安全信息交换所：",
  "article20_question102_footnote_6": "<sup>6</sup>例如，如果贵国<i>没有这种信息</i>，则应选择没有信息。",
  "article20_question102_a_title": "用于执行议定书的现有的国家立法、条例和准则，以及缔约方用于事先知情同意程序所需要的信息（第20条第3款（a）项）",
  "article20_question102_b_title": "适用于拟直接作食物或饲料或加工之用的进口改性活生物体的立法、条例和准则（第11条第5款）",
  "article20_question102_c_title": "双边、多边及区域协议和安排（第14条第2款和第20条第3款（b）项）",
  "article20_question102_d_title": "国家主管部门（第19条第2和第3款）和国家联络人（第19条第1和第3款）的详细联系方式以及紧急联系方式（第17条第3款（e）项）",
  "article20_question102_e_title": "某一缔约方对改性活生物体的过境所作的决定（第6条第1款）",
  "article20_question102_f_title": "某一缔约方对进口用于封闭使用的改性活生物体所作的决定（第6条第2款）",
  "article20_question102_g_title": "关于在贵国管辖范围内发生的释放将会导致或可能导致改性活生物体的无意越境转移，从而可能对生物多样性造成重大不利影响的通知（第17条第1款）",
  "article20_question102_h_title": "关于改性活生物体的非法越境转移的案例信息（第25条第3款）",
  "article20_question102_i_title": "关于进口有意向环境中引入的改性活生物体的决定（第10条第3款）",
  "article20_question102_j_title": "关于特定改性活生物体进口时国内条例适用性的信息（第14条第4款）",
  "article20_question102_k_title": "关于在国内使用可能属于越境转移的拟直接作食物或饲料或加工之用的改性活生物体的决定（第11条第1款）",
  "article20_question102_l_title": "关于在国内监管框架下（第11条第4款）或按照议定书附件三（第11条第6款）进口拟直接作食物或饲料或加工之用的改性活生物体的决定",
  "article20_question102_m_title": "关于针对拟直接作食物或饲料或加工之用的改性活生物体所采用的相关框架的声明（第11条第6款）",
  "article20_question102_n_title": "关于改性活生物体有意越境转移的决定的审查和更改（第12条第1款）",
  "article20_question102_o_title": "可能在通知进口缔约方的同时发生的有意越境转移案例（第13条第1款（a）项）",
  "article20_question102_p_title": "由各缔约方赋予豁免权的改性活生物体（第13条第1款（b）项）",
  "article20_question102_q_title": "在监管过程中产生的改性活生物体风险评估或环境审查以及有关产品相关信息的概述（第20条第3款（c）项）",
  "article20_question103_title": "若您对第102个问题中任何一项的回答为有信息<i>但尚未向生物安全信息交换所提交或只向生物安全信息交换所提交了一部分</i> ，请简要说明:",
  "article20_question104_title": "贵国是否已建立相关机制以协调生物安全信息交换所国家联络人、《卡塔赫纳生物安全议定书》联络人以及国家主管部门以便向生物安全信息交换所提供信息？",
  "article20_question105_title": "本报告所述期间，贵国是否在改性活生物体的决策过程中使用了向生物安全信息交换所提供的信息？",
  "article20_question106_title": "本报告所述期间，贵国访问和使用生物安全信息交换所时是否遇到困难？",
  "article20_question107_title": "贵国是否设有国家生物安全信息交换所？",
  "article20_question108_title": "请在此提供贵国执行第20条的更多细节：",
  "article21_title": "第21条 — 机密资料",
  "article21_question109_title": "贵国是否制定了相关程序保护从议定书收到的机密资料？",
  "article21_question110_title": "贵国是否允许通知人决定哪些资料列为机密？",
  "article21_question111_title": "请在此提供贵国执行第21条的更多细节：",
  "article22_title": "第22条 — 能力建设",
  "article22_question112_title": "贵国是否拥有可预测和可靠供资来进行能力建设以有效执行议定书？",
  "article22_question113_title": "贵国在开发和/或加强生物安全人力资源和机构能力方面是否得到了外部支持？",
  "article22_question114_title": "若您对第113个问题的回答为<i>是</i>或<i>在某种程度上是</i>，那么贵国是如何得到这些支持的？",
  "article22_question115_title": "贵国是否向其他缔约方提供支持资助其开发和/或加强生物安全人力资源和机构能力？",
  "article22_question116_title": "若您对第115个问题的回答为<i>是</i>，那么贵国是如何提供这些支持的？",
  "article22_question117_title": "本报告所述期间，贵国是否使用全环基金资金透明分配系统（STAR）的拨款开展生物安全能力建设？",
  "article22_question118_title": "本报告所述期间，贵国是否采取行动发展和/或加强生物安全人力资源和机构能力？",
  "article22_question119_title": "若您对第118个问题的回答为<i>是</i>或<i>在某种程度上是</i>，那么在下列哪些领域开展了此类行动（请选择所有适用项）？",
  "article22_question119_options0_title": "机构能力和人力资源",
  "article22_question119_options1_title": "将生物安全纳入跨部门和部门立法、政策及机构（将生物安全纳入主流）",
  "article22_question119_options2_title": "风险评估及其他科学技术专业知识",
  "article22_question119_options3_title": "风险管理",
  "article22_question119_options4_title": "生物安全方面的公众认识、参与和教育",
  "article22_question119_options5_title": "信息交流和数据管理，包括参与生物安全信息交换所的活动",
  "article22_question119_options6_title": "在次区域、区域和国际层次上的科学、技术和机构合作",
  "article22_question119_options7_title": "技术转让",
  "article22_question119_options8_title": "改性活生物体的识别，包括其检测",
  "article22_question119_options9_title": "社会-经济因素",
  "article22_question119_options10_title": "执行《议定书》第18.2条的单据要求",
  "article22_question119_options11_title": "机密资料的处理",
  "article22_question119_options12_title": "改性活生物体无意和/或非法越境转移的应对措施",
  "article22_question119_options13_title": "与改性活生物体相关的科学生物安全研究",
  "article22_question119_options14_title": "考虑对人类健康的风险",
  "article22_question119_options15_title": "赔偿责任和补救",
  "article22_question120_title": "若您对第118个问题的回答为<i>是</i>或<i>在某种程度上是</i>，那么贵国在发展和/或加强能力建设时是否使用了能力建设材料，包括在线资料？",
  "article22_question121_title": "本报告所述期间，贵国是否开展过能力建设需求评估？",
  "article22_question122_title": "贵国是否仍有能力建设方面的需求？",
  "article22_question123_title": "若您对第122个问题的回答为“<i>是</i>”，那么下列哪些领域仍需要能力建设（请选择所有适用项）？",
  "article22_question123_options0_title": "机构能力和人力资源",
  "article22_question123_options1_title": "将生物安全纳入跨部门和部门立法、政策及机构（将生物安全纳入主流）",
  "article22_question123_options2_title": "风险评估及其他科学技术专业知识",
  "article22_question123_options3_title": "风险管理",
  "article22_question123_options4_title": "生物安全方面的公众认识、参与和教育",
  "article22_question123_options5_title": "信息交流和数据管理，包括参与生物安全信息交换所的活动",
  "article22_question123_options6_title": "在次区域、区域和国际层次上的科学、技术和机构合作",
  "article22_question123_options7_title": "技术转让",
  "article22_question123_options8_title": "改性活生物体的采样、检测和识别",
  "article22_question123_options9_title": "社会-经济因素",
  "article22_question123_options10_title": "执行关于处理、运输、包装和标志的单据要求",
  "article22_question123_options11_title": "机密资料的处理",
  "article22_question123_options12_title": "改性活生物体无意和/或非法越境转移的应对措施",
  "article22_question123_options13_title": "与改性活生物体相关的科学生物安全研究",
  "article22_question123_options14_title": "考虑对人类健康的风险",
  "article22_question123_options15_title": "赔偿责任和补救",
  "article22_question124_title": "若您对第122个问题的回答为<i>是</i>，那么贵国是否已确定能力建设需求的先后次序？",
  "article22_question125_title": "贵国是否有正常运行的国家机制来协调生物安全方面的能力建设举措？",
  "article22_question126_title": "请在此提供贵国执行第22条的更多细节，包括贵国获得全环基金资金的经验：",
  "article23_title": "第23条 — 公众意识和参与",
  "article23_question127_title": "贵国的立法或政策是否涉及生物安全方面的公众意识、教育和参与？",
  "article23_question128_title": "贵国是否已建立机制确保公众获得关于改性活生物体的信息？",
  "article23_question129_title": "贵国是否建立机制来促进和推动公众参与改性活生物体的决策过程，包括磋商？",
  "article23_question130_title": "贵国是否向公众通报公众参与改性活生物体相关决策过程的现行方式？",
  "article23_question131_title": "本报告所述期间，贵国在改性活生物体决策过程中征求过几次公众意见？",
  "article23_question132_title": "本报告所述期间，贵国是否向公众公布改性活生物体决定的结果？",
  "article23_question133_title": "贵国是否告知公众如何访问生物安全信息交换所？",
  "article23_question134_title": "贵国是否将生物安全列入了教育和培训课程？",
  "article23_question135_title": "贵国是否制定了国家生物安全传播战略？",
  "article23_question136_title": "贵国是否有生物安全意识和外联方案？",
  "article23_question137_title": "贵国目前是否有国家生物安全网站？",
  "article23_question138_title": "本报告所述期间，贵国是否获取参考资料以促进公众的生物安全意识、教育和参与？",
  "article23_question139_title": "请在此提供贵国执行第23条的更多细节：",
  "article24_title": "第24条 — 非缔约方",
  "article24_question140_title": "贵国是否与非缔约方就改性活生物体的越境转移问题订立任何双边、区域及多边协定？",
  "article24_question141_title": "本报告所述期间，贵国是否从非缔约方进口改性活生物体？",
  "article24_question142_title": "本报告所述期间，贵国是否向非缔约方出口改性活生物体？",
  "article24_question143_title": "若您对第141和/或142个问题的回答为“<i>是</i>”，那么这些改性活生物体的越境转移是否符合《卡塔赫纳生物安全议定书》的目标？",
  "article24_question144_title": "请在此提供贵国执行第24条的更多细节：",
  "article25_title": "第25条 - 非法越境转移<sup>7</sup>",
  "article25_footnote_7": "<sup>7</sup>根据第CP-VIII/16号决定通过的工作定义，“‘非法越境转移’指的是违反有关缔约方为执行《议定书》而采取的国内措施进行的改性活生物体越境转移”。",
  "article25_question145_title": "贵国是否已在国内采取适当措施，防止和/或惩处违反国内《卡塔赫纳议定书》执行措施而进行改性活生物体越境转移的行为？",
  "article25_question146_title": "本报告所述期间，贵国获悉多少个改性活生物体非法越境转移案件？",
  "article25_question147_title": "若您对第146个问题的回答为<i>贵国曾获悉非法越境转移案件</i>，那么是否确定了改性活生物体的来源？",
  "article25_question148_title": "请在此提供贵国执行第25条的更多细节：",
  "article26_title": "第26条 — 社会-经济因素",
  "article26_question149_title": "贵国是否有任何具体做法和要求，以便将改性活生物体的社会-经济影响纳入决策过程？",
  "article26_question150_title": "贵国是否为考虑社会-经济因素而使用参考材料？",
  "article26_question151_title": "本报告所述期间，贵国是否在决策过程中考虑了改性活生物体造成的社会-经济影响？",
  "article26_question152_title": "请在此提供贵国执行第26条的更多细节：",
  "article28_title": "第28条 — 财务机制和财政资源",
  "article28_question153_title": "本报告所述期间，贵国除国家经常预算拨款外，调动了多少资金（美元等值）来支持《卡塔赫纳议定书》的执行？",
  "article28_question153_option0_title": "1至4,999美元",
  "article28_question153_option1_title": "5,000至49,999美元",
  "article28_question153_option2_title": "50,000至99,999美元",
  "article28_question153_option3_title": "100,000至499,000美元",
  "article28_question153_option4_title": "500,000美元或以上",
  "article33_title": "第33条 — 监测与汇报",
  "article33_description": "<i>第33条要求缔约方对《卡塔赫纳议定书》为之规定的<i><u>各项义务的履行情况</u></i>进行监测，并就其为履行《卡塔赫纳议定书》所采取的措施向作为本议定书缔约方会议的缔约方大会作出汇报。</i>",
  "article33_question154_title": "贵国是否启动了监测和强制执行《卡塔赫纳议定书》的系统？",
  "cooperation_title": "合作",
  "cooperation_description": "<i>《卡塔赫纳议定书执行计划》长期目标B.4涉及国家、区域和国际各级在生物安全问题上的合作与协调。以下是与此目标有关的问题，包括与议定书不同条款中所述合作有关的问题。</i>",
  "cooperation_question155_title": "本报告所述期间，贵国是否在以下方面与其他缔约方进行合作：",
  "cooperation_question155_a_title": "交流科学、技术和机构知识；",
  "cooperation_question155_b_title": "确定可能对生物多样性的保护和可持续利用产生不利影响的改性活生物体或具体特性？（第16条第5款）",
  "cooperation_question155_c_title": "关于改性活生物体的任何社会-经济影响的研究和信息交流？（第26条第2款）",
  "cooperation_question155_c_option0_title": "是否包括关于改性活生物体对土著人民和地方社区的社会-经济影响的研究和信息交流?",
  "cooperation_question155_d_title": "公众意识、教育和参与？（第23条第1款（a）项）",
  "cooperation_question155_e_title": "加强执行议定书的能力？",
  "cooperation_question156_title": "本报告所述期间，贵国是否参加过执行议定书的双边、区域或多边活动？",
  "cooperation_question157_title": "贵国是否出台机制让土著人民和地方社区以及不同部门的相关利益攸关方参与议定书的执行？",
  "cooperation_question157_a_title": "让<i>土著人民和地方社区</i>参与的机制",
  "cooperation_question157_b_title": "让<i>不同部门相关利益攸关方</i>参与的机制",
  "cooperation_question158_title": "请在此提供贵国生物安全合作方面的更多细节：",
  "nagoyaKualaLumpur_title": "《关于赔偿责任和补救的名古屋-吉隆坡补充议定书》",
  "nagoyaKualaLumpur_description": "<i>也邀请非补充议定书缔约方的卡塔赫纳议定书缔约方答复下列问题</i>",
  "nagoyaKualaLumpur_question159_title": "贵国是否《关于赔偿责任和补救的名古屋－吉隆坡补充议定书》的缔约方？",
  "nagoyaKualaLumpur_question159_options0_title": "是否启动加入《补充议定书》的程序？",
  "nagoyaKualaLumpur_question160_title": "贵国是否采取了执行《补充议定书》的必要措施？",
  "nagoyaKualaLumpur_question160_options0_title": "国家措施充分到位",
  "nagoyaKualaLumpur_question160_options1_title": "国家措施部分到位",
  "nagoyaKualaLumpur_question160_options2_title": "仅采取了临时措施",
  "nagoyaKualaLumpur_question160_options3_title": "仅有措施草案",
  "nagoyaKualaLumpur_question160_options4_title": "未采取任何措施",
  "nagoyaKualaLumpur_question161_title": "为执行《补充议定书》出台了哪些文书（请选择所有适用项）？",
  "nagoyaKualaLumpur_question161_options0_title": "一项或多项国家法律",
  "nagoyaKualaLumpur_question161_options1_title": "一项或多项国家条例",
  "nagoyaKualaLumpur_question161_options2_title": "一套或多套准则",
  "nagoyaKualaLumpur_question161_options3_title": "未制定任何文书",
  "nagoyaKualaLumpur_question162_title": "贵国是否有行政或法律文书要求在以下情况下采取应对措施：",
  "nagoyaKualaLumpur_question162_a_title": "改性活生物体造成损害时？",
  "nagoyaKualaLumpur_question162_b_title": "如不采取应对措施非常有可能造成损害时？",
  "nagoyaKualaLumpur_question163_title": "若您对162a个的回答为“<i>是</i>”，那么这些文书是否对经营人提出要求（请选择所有适用项）？",
  "nagoyaKualaLumpur_question163_options0_title": "是，经营人必须告知主管部门损害情况",
  "nagoyaKualaLumpur_question163_options1_title": "是，经营人必须对损害作出评价",
  "nagoyaKualaLumpur_question163_options2_title": "是，经营人必须采取应对措施",
  "nagoyaKualaLumpur_question163_options3_title": "是，其他要求",
  "nagoyaKualaLumpur_question164_title": "若您对162a的回答为“<i>是</i>”，那么这些文书是否要求经营人采取应对措施以避免损害？",
  "nagoyaKualaLumpur_question165_title": "若您对162a或162b的回答为“<i>是</i>”，那么这些文书是否提供了“经营人”的定义？",
  "nagoyaKualaLumpur_question166_title": "若您对第165个问题的回答为“<i>是</i>”，那么下列选项中哪些可能是“经营人”（请选择所有适用项）？",
  "nagoyaKualaLumpur_question166_options0_title": "许可证持有者",
  "nagoyaKualaLumpur_question166_options1_title": "将改性活生物体投放市场者",
  "nagoyaKualaLumpur_question166_options2_title": "开发者",
  "nagoyaKualaLumpur_question166_options3_title": "生产者",
  "nagoyaKualaLumpur_question166_options4_title": "通知人",
  "nagoyaKualaLumpur_question166_options5_title": "出口者",
  "nagoyaKualaLumpur_question166_options6_title": "进口者",
  "nagoyaKualaLumpur_question166_options7_title": "承运人",
  "nagoyaKualaLumpur_question166_options8_title": "供应者",
  "nagoyaKualaLumpur_question167_title": "是否已确定履行《补充议定书》所列职能的主管部门？",
  "nagoyaKualaLumpur_question168_title": "若您对第167个问题的回答为“<i>是</i>”，那么主管部门有可能采取什么措施（选择所有适用项）？",
  "nagoyaKualaLumpur_question168_options0_title": "查明造成损害的经营人",
  "nagoyaKualaLumpur_question168_options1_title": "对损害作出评价",
  "nagoyaKualaLumpur_question168_options2_title": "确定将由经营人采取的应对措施",
  "nagoyaKualaLumpur_question168_options3_title": "落实应对措施",
  "nagoyaKualaLumpur_question168_options4_title": "向经营人追回对损害作出评价和落实任何应对措施产生的费用和开支",
  "nagoyaKualaLumpur_question169_title": "贵国是否启动了向改性活生物体造成的损害提供财政担保的措施？",
  "nagoyaKualaLumpur_question170_title": "若您对第169个问题的回答为“<i>是</i>”，那么贵国拥有哪些类别的财政担保措施（选择所有适用项）？",
  "nagoyaKualaLumpur_question170_options0_title": "要求提供资金来源可靠的证据",
  "nagoyaKualaLumpur_question170_options1_title": "强制保险",
  "nagoyaKualaLumpur_question170_options2_title": "包括资金在内的政府计划",
  "nagoyaKualaLumpur_question171_title": "贵国是否针对改性活生物体造成的损害规定了民事赔偿责任的规则和程序，或者曾在法院裁决中承认此类损害（请选择所有适用项）？",
  "nagoyaKualaLumpur_question171_options0_title": "是，在民事赔偿责任文书中规定",
  "nagoyaKualaLumpur_question171_options1_title": "是，在法院裁决中承认",
  "nagoyaKualaLumpur_question171_options2_title": "是，在其他文书中规定：",
  "nagoyaKualaLumpur_question172_title": "贵国是否曾经发生过改性活生物体造成损害的事件？",
  "nagoyaKualaLumpur_question173_title": "若您对第172个问题的回答为“<i>是</i>”，那么贵国是否采取了应对措施？",
  "nagoyaKualaLumpur_question174_title": "请在此提供贵国为执行《关于赔偿责任和补救的名古屋－吉隆坡补充议定书》而开展的任何活动的更多细节：",
  "other_title": "其他信息",
  "other_question175_title": "请在此提供与《卡塔赫纳议定书》和《补充议定书》执行情况有关的任何其他信息，包括遇到的任何障碍或阻碍：",
  "Comments_title": "对报告格式的评论",
  "comments_question176_title": "请在此说明您在填写本报告时遇到的任何困难，并提出改进建议。",
  "#meta": {
    "hashedOn": "2024-05-05T18:52:50.373Z",
    "algorithm": "md5",
    "branch": "2024.13.3",
    "hashes": {
      "question": "a97ea56b0e00b2379736ae60869ff66a",
      "yes": "93cba07454f06a4a960172bbd6e2a435",
      "no": "bafd7322c6e97d25b6299b5d6fe8920b",
      "yesAlways": "a05c8bc04b67d979613653210e895247",
      "yesInAllCases": "1fbb1572d2e4f5761e0f3ba34334ad55",
      "yesToSomeExtent": "8fa898fcc98010c94d4ec07080d540ed",
      "inSomeCasesOnly": "701ae6a85673e4f24f000a47e178b8f2",
      "inSomeCases": "b8e26cf259ff5549c33309b9968d2588",
      "yesInSomeCases": "52b54313e436228ef2e0abe5dcb33fce",
      "provideWebsiteAddress": "a1699d551e0a84fdfb1ce6be329c185d",
      "bilateral": "7d11f520a5eb1f219d902c9a4ad29944",
      "regional": "30bdbca82ff4a2f8a149c8e7ebcc9384",
      "multilateral": "80769244ba305975b6648a4970fd7d07",
      "oneToFour": "8c4749675367a1a3e97355315ac1087d",
      "oneToFive": "e475f399207b5768a339eeec08f2d32a",
      "fiveToNine": "abdb674fe66c4a76d250aa4652cf93a6",
      "tenOrMore": "d717af12d953cc1cfa981021acabd019",
      "fiveOrMore": "689d7b0aa9259bb7fa4b92155a45f825",
      "oneToNine": "c8ce70da8b54f1d65128bae7f82979fc",
      "tenTenFortyNine": "0c9bf12635f2c98723d782f45136a413",
      "fiftyToNinetyNine": "940c83b8d21970d4abac2c6e511b8c4c",
      "fiftyOrMore": "e87b8f5cf519156917b197402880c86f",
      "hundredOrMore": "6aaaa80a2c292abba5c0d76f938a439d",
      "other": "6311ae17c1ee52b36e68aaf4ad066387",
      "none": "6adf97f83acf6453d4a6a4b1070f3754",
      "noneDecisions": "75364f00408f7406c5c5df8cdc9f03ee",
      "riskAssessment": "c44e84f897235d008b79075183527b06",
      "riskManagement": "eca6f8f589b057d9b3f53f22223aed27",
      "monitoring": "de40f41b9088f8ff01f09b1863b176b6",
      "isThisNumberAdequate": "d1e747adc6bb607879193c3578818aa6",
      "documentationSpecificToLMOs": "0b1a21b9db496da48e43d2ba43f82042",
      "asPartOfOtherDocumentation": "6783f158bacd49ed500ea20540095f31",
      "provideFurtherInformation": "2080067faa5043c00168a802d5e9a6c5",
      "informationOnInstruments": "42043494af61fcecd79d7941d5145669",
      "general": "0db377921f4ce762c62526131097968f",
      "country": "59716c97497eb9694541f7c3d37b1a4d",
      "notApplicable": "ec220411c447f00b314a4130ee637b7d",
      "notApplicableOnly": "e681a3b45989b468533c4b90ee960bf9",
      "availableOnBch": "fdbbc83d30f1451cce44322548302259",
      "availablePartialyOnBch": "91d0623d65ceaf6225ad491dc2345086",
      "availableNotOnBch": "47602256623f8eec9d801eba17226309",
      "notAvailable": "de66086497baac3fb32035b9e6a76f3c",
      "institutionalCapacity": "05c5ef6d63da33b0a57f06c77e8fa8eb",
      "integrationOfBiosafetyInCrossSectoral": "7d644ee5c84b944a9e6bb8d2903ee361",
      "riskAssessmentExpertise": "cea86a75808b0ce7a5c75f2f19b6c4a0",
      "publicAwarenessBiosafety": "9f20c61df5c59b7d195300194917ea2d",
      "informationExchangeAndDataManagement": "733bce4f906a54d0a585745018c219f2",
      "regionalAdInternationalLevels": "97b8d82c520be1c2123b1c8050d7b213",
      "technologyTransfer": "02a296f22be042b26e2f1c50ff5ffcb0",
      "identificationOfLMOsDetection": "e7244f020f0bf8162a0528cc79118357",
      "socioeconomicConsiderations": "8e2499388b3dd845deb8b7877000cff1",
      "implementationProtocol": "5fe1e7d11c1b20a214a13ae97b82cec6",
      "handlingConfidentialInformation": "bf9ce9519c142f38af0bc4ab90ed3f2d",
      "measuresOfLMOs": "6d77c17def4f2bad6720b8e9c95df796",
      "scientificLMOs": "92b18031c5c30767c0ccac8a384041ad",
      "takingHHumanealth": "3351fd5d09602422863ae0fd459e7d10",
      "liabilityAnRedress": "24a6b3180c9418e4262a441861a53b91",
      "article2_title": "5cc63abd8d0d57c8ab93f1d5ec880d12",
      "article2_description": "ba4b230afd2a340de4c465ecfbe4494a",
      "article2_question7_title": "3be813282a7cc8945c19501db68fbc0d",
      "article2_question7_options0_title": "af67d99c8b97de1672a68df0092093c4",
      "article2_question7_options1_title": "10d2cf1ab448d64bb1b4b07ac4861649",
      "article2_question7_options2_title": "ad3027e19d25a83b801a374b4c2959a4",
      "article2_question7_options3_title": "7fc68e4cbd38a8ef01170fb7be97b66e",
      "article2_question7_options4_title": "7b55ce25b4b47c8b73a370f25cbed22d",
      "article2_question8_title": "6fa11f67e611662790d16f2ace3a10bf",
      "article2_question8_options0_title": "33b4cc297f825c1637f23cfc9e007db3",
      "article2_question8_options1_title": "a225954a3e6adbd72ba3be6665970cfe",
      "article2_question8_options2_title": "2df89da64f9d701cddf425dd2688b9c2",
      "article2_question8_options3_title": "0c71dc82baa716a47efb8ae6d7a8dcd4",
      "article2_question8_options4_title": "82a2681f3fb95e3d671ad06400742086",
      "article2_question9_title": "4af986ec015baf80883d075364ba605a",
      "article2_question10_title": "8e796d727d9b2406f28dd77650a3952b",
      "article2_question10_question0_title": "69a679b2c2cf9f3a91fe2e99ba632fc1",
      "article2_question11_title": "74ed4084c5facadd72c20cced0f86725",
      "article2_question12_title": "92d2bc95b738526bbb9d82c14b67bb4f",
      "article2_question13_title": "6ed5d353456b257554dbe2b3f1b474d4",
      "article5_title": "4e317eb85497776ac873b8918e333004",
      "article5_question14_title": "89e6464bd5722b6427f6380ef33c3c99",
      "article5_question15_title": "6e06b165c0a75f196224cc60ffa8206f",
      "article6_title": "20a4f6e94fb201c7b6ff5b0b715d8960",
      "article6_question16_title": "2783db95fee418ab0a3147fdd926844a",
      "article6_question17_title": "63b0f4565ecd96bc3276e55ab17b1f93",
      "article6_question18_title": "dd6c6b1be6863eef44bddea5c8a2b44c",
      "article6_question19_title": "a5b620c6ef5bad119920f2008945297f",
      "articles7_10_title": "2c108667af1c6c73f557b3737949377c",
      "articles7_10_question20_title": "c24efc7b8335590ddb6d3bb6d825e6cd",
      "articles7_10_question21_title": "be9d086a0d6844f3f91a14108ccc4d7a",
      "articles7_10_question22_title": "ea3870651aa7b3c42e227edfa7c3d489",
      "articles7_10_question23_title": "5f4af4a3f2dcc3bd0d09745c6817240c",
      "articles7_10_question24_title": "13fcbfb674b773b9ba86533a048b5213",
      "articles7_10_question25_title": "5ed8d0e8f2612e0fcc2367f2905addde",
      "articles7_10_question25_question0_title": "6af2a44d1ca81f405b2780c6c58e4e3a",
      "articles7_10_question25_question1_title": "35d3c9d6559da302aed8de338f850072",
      "articles7_10_question26_title": "83edd94a80cc42d6ec67936b3bc7c90f",
      "articles7_10_question26_question0_title": "a623aa206eeaa52343d9c495404cb964",
      "articles7_10_question27_title": "46da4e6af7d63434f705d69c7c6bbcdf",
      "articles7_10_question27_question0_title": "113010039896a11b08833fc42c96260b",
      "articles7_10_question27_question1_title": "60feb07126439578f5d6e8c592db6382",
      "articles7_10_question27_question1_question0_title": "2029df4850115672f4dea4f36f3cf637",
      "articles7_10_question27_question2_title": "5862390854284a25a34da1dae75b9e84",
      "articles7_10_question27_question2_question0_title": "ca49f2e7f098a3f9ddc7e045b7065618",
      "articles7_10_question27_question3_title": "24a9a1ed3f9957c11a97fb02cc873b79",
      "articles7_10_question27_question4_title": "7b1d2d6f93dee0ff6faa8b7fffdbed90",
      "articles7_10_question28_title": "760630f2a8638c1ec97c3706c6cc61de",
      "articles7_10_question29_title": "ceb8a2ecb8119bca326e105b8e0f15f8",
      "articles7_10_question30_title": "94dfe4eb83295e67796b58038babddef",
      "article11_title": "f6a6cc82b7b7cb9b897f9744ac3a0750",
      "article11_question31_title": "a45bbb056db535b6c44db75c696f8dbf",
      "article11_question32_title": "d552a41a666536ad2c7f8e37bfcf99c2",
      "article11_question33_title": "3bc5945f6e98a28ded72befeeab112ea",
      "article11_question34_title": "c50703bdf32d099a338a55672a7e5de1",
      "article11_question35_title": "b61c7326429f6d498d26b88c45430f59",
      "article11_question36_title": "8db41589142a53a9dca44bf9a5ff22d1",
      "article12_title": "32b746c09b91e5daf8ed2b6e27f32abe",
      "article12_question37_title": "67ad6ba15ce8a85633becbd3f0d92a50",
      "article12_question38_title": "b386dee54deecdbef24992b1e2f896fc",
      "article12_question39_title": "b7110fa4004723eeda39a47a2295e615",
      "article12_question40_title": "6d9272750b1c5abda536bacee1c59faa",
      "article12_question41_title": "e3e7ab4441026e992f03edb8b730a13a",
      "article12_question42_title": "37083fffbd470787ecd2120db20efcf6",
      "article12_question43_title": "d77873a05b9ecc7c94cc543d4e2217d2",
      "article12_question43_question0_title": "9752e0ffeeda1decaf6fe2819effbed9",
      "article12_question43_question1_title": "578f13dc53b3eefecaa17597172f987d",
      "article12_question44_title": "0e7cc06a9f83ff759020cc38215f5972",
      "article13_title": "4ff03ba84e8db6cd2ad40d23e7425830",
      "article13_question45_title": "0e13f4625e2097c2f93e28b05512c848",
      "article13_question46_title": "953bc0ae63d68c666072b7ee0ff9dd99",
      "article13_question47_title": "fec4c15e8bebf7387e78ac89c3dfcec9",
      "article13_question48_title": "1d40c0adef32c9d89f18b8d21b145595",
      "article13_question49_title": "932e9d679b75b6d1ea9c1fddf2a965e2",
      "article14_title": "194c1a3543e8d8399fb4b663eded5f0f",
      "article14_question50_title": "dc97c7d1c334514a6b276bdf351839e6",
      "article14_question51_title": "03c873e4238bf0fe4d1f24c6e23505a4",
      "article14_question52_title": "3ae85dd7ce005553b286c2a5ef51a511",
      "articles15_16_title": "36fccb325dcdb3d174aee41d97b06bc4",
      "articles15_16_question53_title": "3881df5dc9bee7ff744b58e6a1eace77",
      "articles15_16_question53_a_title": "aa7bd175d9ffaa1f360b230c94c86e27",
      "articles15_16_question53_a_option0_title": "ce3f9ac80863b8b6eadfa26e761fd825",
      "articles15_16_question53_a_option1_title": "d368d6cb4275988570c0c11343838b5d",
      "articles15_16_question53_a_option2_title": "3fdb901403644d9cd1229e4007d24a77",
      "articles15_16_question53_a_option3_title": "a5a9e5defdb5b6e8c54a58c70f7136fb",
      "articles15_16_question54_title": "788af2f0913b4ceac9fc7fc8f8e4bee3",
      "articles15_16_question55_title": "4bbf61ab1602ba3e5ff821ff966cfb76",
      "articles15_16_legend_55_68": "527b5137496e9e74dab342e208e4174b",
      "articles15_16_question56_title": "fdbf9b890cc97c87c76cce61a4dd28f2",
      "articles15_16_question57_title": "15b40e171df57121aa2de2e88f33db78",
      "articles15_16_question57_option0_title": "516f7e39e48b9405d61f3e9ee6826af1",
      "articles15_16_question57_option1_title": "17056520eec89cf41c9e28ef77551f7f",
      "articles15_16_question57_option2_title": "06072450a1562f13aebb5b44908feb03",
      "articles15_16_question57_option3_title": "512727140e8ecb09249a467a3b102877",
      "articles15_16_question57_option4_title": "3646817246b26ab9b9e20e6e73c4ed89",
      "articles15_16_question57_option5_title": "e742469b1b2cceb6132b675e148d5dc9",
      "articles15_16_question58_title": "072ce6ae03bfe426d064679e3bd0bac9",
      "articles15_16_question59_title": "d94a9adeb4d1b21d7efac1a6f7e5436d",
      "articles15_16_question59_a_title": "36ef294106d26554a97e70fab6e57074",
      "articles15_16_question59_b_title": "8f9be4650477f143d28943b7a863a103",
      "articles15_16_question60_title": "8df8deed8beb5bd681f7dbca9e78c8d8",
      "articles15_16_question61_title": "1a489b72c105717009c2b6af052cec0e",
      "articles15_16_question62_title": "0c713aba7b350e90463c77fd9c3e66af",
      "articles15_16_question62_footnote_1": "2a840b5bfb06a1cb5b5a5382f346a4f4",
      "articles15_16_question63_title": "9b4e1381bb8548d8eaa4f54100b94839",
      "articles15_16_question64_title": "c008eb86a841711d8227829c05362c12",
      "articles15_16_question65_title": "df5fb12b37c25ef133847a34ffb61c2b",
      "articles15_16_question66_title": "bc723071b2bfc6f6007594c2a58baaca",
      "articles15_16_question67_title": "34623185e6627427ec91cb3e138e3cd5",
      "articles15_16_question67_footnote_2": "58a26445ab99b142aeef3128fed0d189",
      "articles15_16_question68_title": "cdc8f555c151c35dd50dd4d00d01f94a",
      "articles15_16_legend_69_72": "251ee51de82f00ef1040401053769710",
      "articles15_16_question69_title": "253698bf76f2ead674da6b643b957d68",
      "articles15_16_question69_a_title": "72c22c0ddb57940aa291dcb1645a3677",
      "articles15_16_question69_b_title": "30f6aecfc15a0ab94c7e9ca927fad02a",
      "articles15_16_question69_c_title": "d5adeb25825937ee0adb6e0eff866f6c",
      "articles15_16_question69_d_title": "e6f1f09a7a59e39877b30cb0c5645c58",
      "articles15_16_question70_title": "533a3294dc4e48c3a390fe6eabb9c0b2",
      "articles15_16_question71_title": "e3b72911900c9d3f4970f79dfeab6a64",
      "articles15_16_question71_question0_title": "24b14022ce6c9eb6b3751311b6b3f214",
      "articles15_16_question71_question0_option0_title": "b49cbd24e7402f6ee97fe191af8de467",
      "articles15_16_question71_question0_option1_title": "14127a879a2baa5dfde853feea58f834",
      "articles15_16_question71_footnote_3": "be3281c539fea499d4ae836894f851e0",
      "articles15_16_question71_footnote_4": "b78faa09f9cc6a3fb9b1ceed3a87bbea",
      "articles15_16_question71_question0_option2_title": "c6d3e6e3df4d5019942998d84b07e21d",
      "articles15_16_question72_title": "1aab5bf9407f72ecbc4e0b8184f5a260",
      "article17_title": "c87709ef330279bf4c4b9ab0cb89df89",
      "article17__footnote_5": "ef76c0c8423e330ff16a7b811db2e141",
      "article17_question73_title": "c1128b1684e739fa88900ea1288d9216",
      "article17_question74_title": "228b3369dca98c543dd580da41ee0d9d",
      "article17_question75_title": "59927148ad9b27f3a9b0cab35168424f",
      "article17_question76_title": "209126df7e91eeda4c4cb1a9f01defbe",
      "article17_question77_title": "bd1a8da745e89d55573a044201dd83b7",
      "article17_question78_title": "5b683ce69111b6feecbac5455d962332",
      "article18_title": "73a2945f4584858ea9e8abd116cb4ce4",
      "article18_question79_title": "8f476888968dc0930de52565bae839d6",
      "article18_question80_title": "a38280ec6482a3bb3b1d3fa072ec79eb",
      "article18_question81_title": "5b0fa0e7709e7e326a92498fd5f65ecf",
      "article18_question82_title": "cba5b06020ec5d4881106271cfaf7ee5",
      "article18_question83_title": "6c7e37d4c687010a78a345f0f6b88852",
      "article18_question84_title": "05450d77543944e8bc2a401f17905089",
      "article18_question85_title": "54bab7163ff803bac4fe00ff84aa7de1",
      "article18_question86_title": "61fb08a9ff4910649bc135bdd26d45e3",
      "article18_question87_title": "4aa559a02dd37fb9540561c7eb7d5bae",
      "article18_question88_title": "adca2f5b46e9d4ecdc08d2cdfb345b99",
      "article18_question89_title": "260aafa6a684ddecc7724f9ad8a5398a",
      "article18_question90_title": "905725e4ffbc5f7582f672ad14cec6d5",
      "article18_question90_a_title": "a27903155c5f6148bf1cf89c79f84520",
      "article18_question90_b_title": "d88c492c3581c72aa5d02fc33ebb4e5f",
      "article18_question91_title": "852423bf6ff1037d9963da94fa0d74b7",
      "article18_question91_a_title": "963f79e61fcf16e7d793729cb8117b00",
      "article18_question91_b_title": "0c2c156be82816a6c0d7d6983b68d297",
      "article18_question92_title": "cbb858166b680f7a52bbbfae3d4b2876",
      "article18_question92_a_title": "3f4626482168b4520db0061834101647",
      "article18_question92_b_title": "ad45d6b3803dd223c205e6cb93c564ec",
      "article18_question93_title": "e49de0b56acc54d1200d4726753e58e6",
      "article18_question94_title": "bd1aa295b07867a80641f3455828c974",
      "article18_question94_a_title": "6ac645130721b772701a6c6d05193070",
      "article18_question94_b_title": "009d617424f2c4e8d861c544021f930e",
      "article18_question95_title": "08369648e892b8f6e80faf6ed79a679d",
      "article18_question96_title": "de4fbdaa89de2c8d3d01a21d12c90f75",
      "article18_question97_title": "cba572b27b2ea1eed9722909db07bb50",
      "article19_title": "d2b23836a16f374bf4d9ef15eb934248",
      "article19_question98_title": "0d9dce1864f35235d56c41335988bfce",
      "article19_question98_option0_title": "31e51738f1adc4bc78914db5a55774fc",
      "article19_question98_option1_title": "5b1b814e834c326366ff452131ce3190",
      "article19_question99_title": "28acf278ff1abedad4f829a0bb9e7654",
      "article19_question100_title": "4d227995898bdf612d78965f05c9b7fa",
      "article19_question101_title": "b6844d2391881e14b976197fad83b015",
      "article20_title": "c76c37acc71f612a38c6eed19dfb0e3c",
      "article20_question102_title": "d9cafc071b1beeb224d3038224be36ab",
      "article20_question102_footnote_6": "cc938e2cf31577e685d5a9f6507b45ff",
      "article20_question102_a_title": "0b5e83a37ec74f2d3a6c82b61ba73e6f",
      "article20_question102_b_title": "b32ed924fa8bb616f4332d2e455bf110",
      "article20_question102_c_title": "e8532a57fe089fa5d7ce00e5c457f7b7",
      "article20_question102_d_title": "26bd28e753dd1d74ca54fc4b3e4fda80",
      "article20_question102_e_title": "377db1969645e265c21a8865418e8f95",
      "article20_question102_f_title": "25098ee57566d1e88d58422907a3288f",
      "article20_question102_g_title": "671b6b5b9f6303cb8081fbf9682f3bed",
      "article20_question102_h_title": "8079643ec84dad979f81676420ec526d",
      "article20_question102_i_title": "2129cc338d1536695faf9769b1dbbbfb",
      "article20_question102_j_title": "de494f612f2edaf8dfe098476b3b3e33",
      "article20_question102_k_title": "36d9154ed360c60af160b79fd2535bbb",
      "article20_question102_l_title": "83a7bf551e49791444899ebebfb61aea",
      "article20_question102_m_title": "668eeba7c283715fbfd95043c158998c",
      "article20_question102_n_title": "46e5de3de58ce489d96ebacad705b4b1",
      "article20_question102_o_title": "fae3932f490ad2fc941516db467ef4cf",
      "article20_question102_p_title": "1b26b2c5b3f009aabef9b753ab37ba1c",
      "article20_question102_q_title": "be48c605003955bf8fbe1f3cd6ebfdc3",
      "article20_question103_title": "5149af15250ebf0b77279dd6987d5364",
      "article20_question104_title": "ef29072fb70e07c20091d53008bf81d9",
      "article20_question105_title": "b12fccd0cca9b0d49cab3aefbd6e547f",
      "article20_question106_title": "8f55debd029d50caf4ae69d1c52937de",
      "article20_question107_title": "c81a447eddcfd504b1a9a5d35f5a8da3",
      "article20_question108_title": "2493937629a340ba882d5a601dfd20d6",
      "article21_title": "127af15d1bac1071a6763038e1e39b16",
      "article21_question109_title": "b6944eb683ac01be5ca6fe34167e358a",
      "article21_question110_title": "b2e2be70f02a29b9feca3f37cff2d125",
      "article21_question111_title": "767daea143a4e61ea0b3d44772332de3",
      "article22_title": "c15fa09f019e40522d3dc7ef2a5e0e16",
      "article22_question112_title": "0bd33620a10f37e17575aff4349997a8",
      "article22_question113_title": "27ce8d20dd13bc0b8a6d8bc6fee7d5a5",
      "article22_question114_title": "8f706c3e6deba76bf99c1c8b514912ab",
      "article22_question115_title": "f4dc40196aa40d3f2fd9300b30574733",
      "article22_question116_title": "6850f78e18d0519f860e6853074e87a7",
      "article22_question117_title": "89525a0b0d7ddb26a55b268c57ca810e",
      "article22_question118_title": "8c001638961f731e99c49d576bc35c61",
      "article22_question119_title": "a7335d1311a4867923fbb1ee6fd30882",
      "article22_question119_options0_title": "05c5ef6d63da33b0a57f06c77e8fa8eb",
      "article22_question119_options1_title": "7d644ee5c84b944a9e6bb8d2903ee361",
      "article22_question119_options2_title": "cea86a75808b0ce7a5c75f2f19b6c4a0",
      "article22_question119_options3_title": "78ec87e68f712039dafd856f3bda4a04",
      "article22_question119_options4_title": "9f20c61df5c59b7d195300194917ea2d",
      "article22_question119_options5_title": "733bce4f906a54d0a585745018c219f2",
      "article22_question119_options6_title": "97b8d82c520be1c2123b1c8050d7b213",
      "article22_question119_options7_title": "02a296f22be042b26e2f1c50ff5ffcb0",
      "article22_question119_options8_title": "e7244f020f0bf8162a0528cc79118357",
      "article22_question119_options9_title": "8e2499388b3dd845deb8b7877000cff1",
      "article22_question119_options10_title": "5fe1e7d11c1b20a214a13ae97b82cec6",
      "article22_question119_options11_title": "bf9ce9519c142f38af0bc4ab90ed3f2d",
      "article22_question119_options12_title": "6d77c17def4f2bad6720b8e9c95df796",
      "article22_question119_options13_title": "92b18031c5c30767c0ccac8a384041ad",
      "article22_question119_options14_title": "3351fd5d09602422863ae0fd459e7d10",
      "article22_question119_options15_title": "24a6b3180c9418e4262a441861a53b91",
      "article22_question120_title": "334cef7f0595c261973492db3e33f7a8",
      "article22_question121_title": "3480930cbbaddf6859d5b2ef67da221d",
      "article22_question122_title": "a213f4d7bba084d6eb7a6bfa3fc9c4bb",
      "article22_question123_title": "e979f29601c2d2b01ac1cfdc1bbad8c5",
      "article22_question123_options0_title": "05c5ef6d63da33b0a57f06c77e8fa8eb",
      "article22_question123_options1_title": "7d644ee5c84b944a9e6bb8d2903ee361",
      "article22_question123_options2_title": "cea86a75808b0ce7a5c75f2f19b6c4a0",
      "article22_question123_options3_title": "78ec87e68f712039dafd856f3bda4a04",
      "article22_question123_options4_title": "9f20c61df5c59b7d195300194917ea2d",
      "article22_question123_options5_title": "733bce4f906a54d0a585745018c219f2",
      "article22_question123_options6_title": "97b8d82c520be1c2123b1c8050d7b213",
      "article22_question123_options7_title": "02a296f22be042b26e2f1c50ff5ffcb0",
      "article22_question123_options8_title": "f48109283dc12199567ca339873b3f09",
      "article22_question123_options9_title": "8e2499388b3dd845deb8b7877000cff1",
      "article22_question123_options10_title": "386189d628ca9dcf3d8acbd2555ba757",
      "article22_question123_options11_title": "bf9ce9519c142f38af0bc4ab90ed3f2d",
      "article22_question123_options12_title": "6d77c17def4f2bad6720b8e9c95df796",
      "article22_question123_options13_title": "92b18031c5c30767c0ccac8a384041ad",
      "article22_question123_options14_title": "3351fd5d09602422863ae0fd459e7d10",
      "article22_question123_options15_title": "24a6b3180c9418e4262a441861a53b91",
      "article22_question124_title": "cba004d88c91e017fefa4863507e120b",
      "article22_question125_title": "e5d32aa3a7c7de9747b9719b2dfcb876",
      "article22_question126_title": "dad7a1836be0b4ffb60b5a9755b16dcb",
      "article23_title": "55a5b921b68d7137ba4ac2027e31433a",
      "article23_question127_title": "77bb6240f0abe75f84d29b0357843f11",
      "article23_question128_title": "40f56d2516acb8a1b9a08dfce72e3fb3",
      "article23_question129_title": "70d62e290cf033a24fae578bbe71326a",
      "article23_question130_title": "cfa3b5a1801a9db3221a87e017d701d1",
      "article23_question131_title": "de2b25a0e66eefc0a954ce075fdf00b8",
      "article23_question132_title": "07415477558f4814339d274daf932ed1",
      "article23_question133_title": "ce0f8fea996af0048dad6359a0643201",
      "article23_question134_title": "e0bdb66f71968d26903c0098f95725c2",
      "article23_question135_title": "0eba4605915a5cb5f63b0753a3365b6d",
      "article23_question136_title": "16b3a15b4a38d6fc38a5335ea7c158c4",
      "article23_question137_title": "64715bf652fc0aa1c4f640ede53aa26a",
      "article23_question138_title": "73603e6e68406737aedffc4a289b60a6",
      "article23_question139_title": "59a073bef86d0b67fb6e84a29d6f6875",
      "article24_title": "f51bf267c189c09b7e70fcdab27f6b9f",
      "article24_question140_title": "6a21b19b1ca25f7b7cea8341920382a2",
      "article24_question141_title": "7bd7dccddbbab084bf0167bbaf57a3b9",
      "article24_question142_title": "70c950e03d036bf2d954a1d99f683df2",
      "article24_question143_title": "f247e4ab2b5a01852235f5f02cd3da75",
      "article24_question144_title": "ca1c9d0451d3f88f6e671cf838b8ec20",
      "article25_title": "a5bb23e8fffe6de71b76c1c23802854d",
      "article25_footnote_7": "9e74f1c1a9dd7639d00bd7855619ee76",
      "article25_question145_title": "677586195493e010ee30abfbf33f4d24",
      "article25_question146_title": "89009fe72ae4ad3ac80e2058fb0c177e",
      "article25_question147_title": "8221f2311b11caeb4569001044e8a7b5",
      "article25_question148_title": "5dac769478a0e93036b9910cf01394d3",
      "article26_title": "ce8fe443028ca43b0f67e8ee123b5321",
      "article26_question149_title": "7831522f6f0ac705a6d85e40993dae45",
      "article26_question150_title": "fd69e68fb4c820162ccb3ce30b2dd4df",
      "article26_question151_title": "6593e5cbcea8d1749792e5db0f3d6dc4",
      "article26_question152_title": "cebfc31647b31fb4df8b677b5a368aa6",
      "article28_title": "20a56483edf87ca230d6e1322596ac7d",
      "article28_question153_title": "6620a8e6b514fb2b67633f7cc44adc9d",
      "article28_question153_option0_title": "c9bc560c8064fc2997b347895d8d7d99",
      "article28_question153_option1_title": "f7bffb1361169037e4289a25271cf334",
      "article28_question153_option2_title": "1f5debe43ff893123279de4ada89703f",
      "article28_question153_option3_title": "48a7fd996117ffb16593c008b61384ff",
      "article28_question153_option4_title": "5df8dbecfd884b42777e8c780972d9b5",
      "article33_title": "8841124073befa522a22cbd8ede760be",
      "article33_description": "ca8cb96db2782b9a409830524c8ac540",
      "article33_question154_title": "ef1d9ad44d6cf2c5f17cf25bb79f4c02",
      "cooperation_title": "45de6e8f0cf71a051fae5da2e0da63a8",
      "cooperation_description": "907dd17c553eaab36b3452999cd36264",
      "cooperation_question155_title": "7cbd13af287f99f8571a372fd5e1fecd",
      "cooperation_question155_a_title": "7b8e174ac52813cd5532e9f43cba7f04",
      "cooperation_question155_b_title": "fa2783754421a78833f1946e534039d7",
      "cooperation_question155_c_title": "78f6ce383738be756137888116940c5c",
      "cooperation_question155_c_option0_title": "8c09641c0f64aefd310b6dbd71fbd461",
      "cooperation_question155_d_title": "3997064a4ee9f0f34cb31fabab4b8643",
      "cooperation_question155_e_title": "4e554fd909a4dae5f864fdcb25d7e5a2",
      "cooperation_question156_title": "74c2b8a93ac9f49198b4ddf317c00ba9",
      "cooperation_question157_title": "6a920e062b67d1beec0e2b8fad4e6bca",
      "cooperation_question157_a_title": "5b98722a3853311156b3e112ed5dd6de",
      "cooperation_question157_b_title": "93d612b661108e2f893386a0f0911b9e",
      "cooperation_question158_title": "ef6501d390b5ff50f45810601b44bfee",
      "nagoyaKualaLumpur_title": "a23124445e7a3ef0d0b08373213268f5",
      "nagoyaKualaLumpur_description": "47edaef1c231339c46d4a826509205cb",
      "nagoyaKualaLumpur_question159_title": "a0cb579dedcfb0c62c96f676d045c93a",
      "nagoyaKualaLumpur_question159_options0_title": "e1a9e8c46f9c4225355b8f4ed20b22f5",
      "nagoyaKualaLumpur_question160_title": "a166a14cb9014fb9ed91c78dd5adc097",
      "nagoyaKualaLumpur_question160_options0_title": "af67d99c8b97de1672a68df0092093c4",
      "nagoyaKualaLumpur_question160_options1_title": "10d2cf1ab448d64bb1b4b07ac4861649",
      "nagoyaKualaLumpur_question160_options2_title": "ad3027e19d25a83b801a374b4c2959a4",
      "nagoyaKualaLumpur_question160_options3_title": "7fc68e4cbd38a8ef01170fb7be97b66e",
      "nagoyaKualaLumpur_question160_options4_title": "7b55ce25b4b47c8b73a370f25cbed22d",
      "nagoyaKualaLumpur_question161_title": "24e26899fcd7f0b7b424c7b94c8232de",
      "nagoyaKualaLumpur_question161_options0_title": "4b900c8c914f4b51861f4353f9b8612f",
      "nagoyaKualaLumpur_question161_options1_title": "5cfedaed85d5ef3205a166fc7376b3a7",
      "nagoyaKualaLumpur_question161_options2_title": "7e0aff0590f2d54a410aa0b9aa369180",
      "nagoyaKualaLumpur_question161_options3_title": "82a2681f3fb95e3d671ad06400742086",
      "nagoyaKualaLumpur_question162_title": "6dcb0999514460eed44acfdb6fdf46bc",
      "nagoyaKualaLumpur_question162_a_title": "be6249cebb818d8420c07700ae2a9b2e",
      "nagoyaKualaLumpur_question162_b_title": "b73ca399f5df113cd47008b4691c5611",
      "nagoyaKualaLumpur_question163_title": "bcce01ec24039ae93f7c3f172fd92245",
      "nagoyaKualaLumpur_question163_options0_title": "9a3b96ea2a506659033543c97d3fff63",
      "nagoyaKualaLumpur_question163_options1_title": "4ba71cd730dd3e4ba780108245456519",
      "nagoyaKualaLumpur_question163_options2_title": "dfb21c0b4e5dab59f432602f125c5296",
      "nagoyaKualaLumpur_question163_options3_title": "987dc21b28d0f6f6d59d3899c210646d",
      "nagoyaKualaLumpur_question164_title": "a65ddd76af04c81746b9ee265a87bf77",
      "nagoyaKualaLumpur_question165_title": "f1aacf9eacf86c49b286e649ce5fb4fe",
      "nagoyaKualaLumpur_question166_title": "5e5293ec5c708fba299a1bcf68e47e21",
      "nagoyaKualaLumpur_question166_options0_title": "8439d09a731614777b59db5edb9b8900",
      "nagoyaKualaLumpur_question166_options1_title": "0a928576d4d7ce4ecb4dc24cfd45b95a",
      "nagoyaKualaLumpur_question166_options2_title": "672caf27f5363dc833bda5099775e891",
      "nagoyaKualaLumpur_question166_options3_title": "a6ad87aadc206f6491720e309821904a",
      "nagoyaKualaLumpur_question166_options4_title": "a8683be34c4605cd25095821a41df850",
      "nagoyaKualaLumpur_question166_options5_title": "d353b8720fcbebe4385ef7a23a43aa22",
      "nagoyaKualaLumpur_question166_options6_title": "15ffab04714cffc08a5e91a1fb62e4ee",
      "nagoyaKualaLumpur_question166_options7_title": "914419aa32f04011357d3b604a86d7eb",
      "nagoyaKualaLumpur_question166_options8_title": "ec136b444eede3bc85639fac0dd06229",
      "nagoyaKualaLumpur_question167_title": "918eccf2b9dcebfd1f5f1b17111136b7",
      "nagoyaKualaLumpur_question168_title": "98d0f298d3d3faed40d0461bafd32c38",
      "nagoyaKualaLumpur_question168_options0_title": "7d321f6c0902d5cca8de0b1b4fee299e",
      "nagoyaKualaLumpur_question168_options1_title": "a938205653388365634295fb3e861fda",
      "nagoyaKualaLumpur_question168_options2_title": "4b355ef4d413e4968bcbd7837d84c9b1",
      "nagoyaKualaLumpur_question168_options3_title": "bbf5ccadf5907940cf050afa64ae834f",
      "nagoyaKualaLumpur_question168_options4_title": "7c080b85a970c79fb85648032f8b5fe5",
      "nagoyaKualaLumpur_question169_title": "c3c645ace3b45287f84731d2994a7e03",
      "nagoyaKualaLumpur_question170_title": "b2b8d579375988edde6d1799c89fa887",
      "nagoyaKualaLumpur_question170_options0_title": "1ab4428a57a9a0139c344fcd483b93a1",
      "nagoyaKualaLumpur_question170_options1_title": "01a714dd1325f130ba307251dfead8b3",
      "nagoyaKualaLumpur_question170_options2_title": "99373883c84ae09e8072c306a58aa372",
      "nagoyaKualaLumpur_question171_title": "6893a921868091d3e7836470e3e02414",
      "nagoyaKualaLumpur_question171_options0_title": "47019fcee4d49d49da58c1ccba3b640b",
      "nagoyaKualaLumpur_question171_options1_title": "f3449bc4d066e592056d5091e97570d2",
      "nagoyaKualaLumpur_question171_options2_title": "99eed23842124368d77399e3ed303399",
      "nagoyaKualaLumpur_question172_title": "2fdd5dad314b1526e4075abba86c2d87",
      "nagoyaKualaLumpur_question173_title": "11f16f3d2666c83b7827c4b45f447f3c",
      "nagoyaKualaLumpur_question174_title": "bdc47859814fd9c87fce8e3976ae1924",
      "other_title": "1d2e7006048aec610a44d2592586470b",
      "other_question175_title": "62109bdfb715c15208d7c39fc47e5b96",
      "Comments_title": "64d103e6258bb8ebcfbb13727fd31701",
      "comments_question176_title": "762e903a023aa32d863fe58430a72ddc"
    }
  }
}